Friday Night Inc, formerly QuikFlo Health Inc. (the “Company“) (CSE:TGIF) (FRANKFURT:1QF) announces that in conjunction with the closing of its previously announced acquisition of interests in two cannabis based businesses located in Las Vegas, Nevada, it has changed its name to Friday Night Inc. and consolidated its shares on a two old for one new basis.
The Company closed its acquisitions of 91% of two Las Vegas based companies – Alternate Medicine Association LC (“AMA”) is a licensed medical marijuana producer in Nevada and the other, Infused Mfg., LLC is a company that provides hemp based and CBD  infused products.  The Company issued a total of 32,750,00 (post-consolidation) common shares and paid US$ 3.4 million in cash, while assuming approximately US$ 1.59 million in debt in respect to these acquisitions.
AMA was the first medical marijuana business licensed in Las Vegas, has current sales of approximately US$ 200,000 per month, and holds both its cultivation and production licenses. Nevada has approved recreational cannabis use, with recreational licenses planned to be issued later this year. Under the current rules, only licensed medical cannabis producers can currently apply for recreational licenses.  
The Infused products company has developed several products using hemp  and CBD infusions, and prepared mixes to which THC can be added by State legal facilities and has achieved growing  sales to date.
The Company closed the fourth and final closing of its previously announced non-brokered private placement. The Company issued, on a post consolidation basis, 4,411,203 units at a price of $0.15 per unit, with each unit consisting of one common share and one half of a share purchase warrant entitling the holder to purchase one additional common share for $0.30 for a period of 2 years from closing. The proceeds of $ 6,616,680.45 will be used for working capital and as well as to fund the acquisitions noted above. Securities issued pursuant to this fourth closing are subject to trading restrictions until October 15, 2017.
The shares of the Company are expected to start trading on the Canadian Securities Exchange on Friday, June 16, 2017 under the symbol “TGIF”.
In conjunction with the acquisitions, Brayden R. Sutton has become the Chief Executive Officer of the Company, as well as being named to the board of directors.  Mr. Sutton brings a successful track record of managing a diverse portfolio of investments through his wholly owned merchant bank. His sectors of specialization over the past 14 years include technology, media and personal health.  Mr. Sutton served as the Executive Vice President for Supreme Pharmaceuticals Inc. (FIRE.V) and his expertise within the legal Cannabis sector has resulted in additional Executive positions, with both public and private companies, at the leading edge of the emerging cannabis industry, including Invictus MD (IMH.V), Aurora Cannabis (ACB.V) and CannaRoyalty (CRZ.C).
Brian Keane of New York, NY has also joined the board. The Company wishes to thank George Tsafalas and David Lane for their service.
Mr. Keane has over 18 years of capital markets, investing and C-level consulting experience in over 100 emerging growth companies in the US, Canada, Caribbean and Asia, transacting over $2 billion in deal value. His previous Wall Street experience includes: Rodman & Renshaw, LLC, Ladenburg Thalmann & Co, TechVest, & Qualified Capital where he focused on life science, biotech, mining and emerging growth companies. He earned a BS from University of Scranton and a JD from New York Law School.
Brayden Sutton, CEO of the Company said “We are excited to enter into one of the most highly anticipated new markets in this sector. With a proven corporate team and some of the best operators in the space running the facilities, the Company is perfectly positioned as a first mover in Clark County.  I could not be more pleased with how far we’ve come and with the opportunities that lie ahead for TGIF shareholders.”
The Company currently has 143,249,666 common shares issued and outstanding.  There are also 12,900,000 warrants outstanding, exercisable at $0.10 for a period of one year, and 17,879,837 warrants outstanding, exercisable at $0.30 for a period of one year. Both sets of warrants contain a forced conversion provision that if the shares of the Company trade at $0.50 or more for a period of 10 trading days, the Company has the option to accelerate the expiry date to no less than 30 days from a press release advising of the same.  The Company also has 17,507,500 incentive options issued to officers, directors, employees and consultants, 17,170,000 of which are exercisable at $0,15, and the balance of 337,500 exercisable at an average cost of $0.46. A total of 31,924,200 common shares are subject to escrow conditions, releasable over the next 3 years.
 
                                                                                                                             
Further Information
For further information relating to this, please contact Brayden Sutton, President of the Company at 604-428-0511 or info@fridaynightinc.com.
Notice regarding Forward Looking Statements: This news release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “should”, “believe” and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. This news release includes forward-looking statements with respect to the regulatory approval in respect to the acquisition of new businesses and raising funds.  Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this news release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com.  Such risk factors may cause the inability of the Company to successfully commercialize any of its biomedical technologies.
 
 
 

  • Company surpassed 5,600 patient prescriptions for its medical cannabis products in Colombia . Prescriptions filled increased over 450% in Q3 2020 over Q2 2020
  • Khiron declared a National Strategic Project by the Government of Colombia , simplifying and accelerating administration and processes for the Company in executing strategic projects in Colombia and for export
  • Subsequent to the quarter, the Company completed a bought deal financing on November 26, 2020 , selling 32,200,000 units at a price of $0.45 per unit for aggregate gross proceeds of $14,490,000 CAD
  • Khiron signed partnerships with 15 clinics and health centres in Colombia , extending education and sales reach further across the country
  • As a result of the Company’s Doctor Zerenia TM telehealth platform more than 25% of the Company’s medical cannabis prescriptions came from outside of Bogota , expanding geographic presence of its Colombian clinics
  • Company achieved first sales of High CBD medical cannabis through private pharmacies in Peru . Additional approval received from Peru’s drug regulatory authority for Company’s High THC cannabis, with first prescriptions anticipated in Q1 2021
  • Expanded medical cannabis E-Learning platform to UK market in partnership with Medical Cannabis Clinicians Society (“MCCS”)
  • Entered an exclusive partnership with Rappi SAS, Latin America’s largest home multi-vertical app platform to distribute the Company’s CPG product portfolio, introducing Kuida products to Rappi users across the LatAm region
  • Signed agreement to distribute the Company’s Kuida TM CBD skincare brand through pharmacy, beauty retail and online markets serving the Hong Kong territory, with first orders expected in Q4 2020
  • Prudent cash use of $5 million in Q3 2020, compared with $4 million in Q2 2020, $12 million in Q1 2020 and $10 million in Q4 2019

 Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe announced today its financial results for the quarter ended September 30, 2020 . These filings are available for review on the Company’s SEDAR profile at www.sedar.com All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less

Shareholders with losses exceeding $50,000 are encouraged to contact the firm

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 1, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB ) securities between February 13, 2020 and September 4, 2020 , inclusive (the “Class Period”).

Keep reading... Show less

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less